ERBB2 Activating Mutation

CI-VAR-00000181Explore in graph →CIViC 2657

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
ERBB2 Activating Mutation	Afatinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID7201 Twenty-eight patients with heavily pretreated stage IV NSCLC had a documented ERBB2 mutation by local testing. Ten patients had pA775_G776insYVMA variants, 2 had M774dup variants, and 16 were unspecif… (full text at CIViC) PMID 30096481 · Peters et al., 2018 · Open in CIViC	civic
Malignant Neoplasm2
ERBB2 Activating Mutation	Afatinib	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11676 In this phase II NCI-MATCH trial, 40 patients with ERBB2 SNVs or ERBB2 insertions/deletions were treated with afatinib. The ORR was 2.7% (90% CI, 0.14-12.2). 37.8% of the patients had SD as the best r… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.